Is Eliquis Given as VTE Prophylaxis After Surgery?
Yes, Eliquis (apixaban) is FDA-approved and guideline-recommended for VTE prophylaxis specifically after major orthopedic surgery (hip or knee replacement), and emerging evidence supports its use after other high-risk surgeries.
FDA-Approved Indications
Apixaban is FDA-approved for prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery 1. The approved dosing is 2.5 mg orally twice daily, with the first dose given 12 to 24 hours post-surgery 1.
Duration of Prophylaxis by Surgery Type:
- Total hip replacement (THR): 32-38 days (approximately 5 weeks) 2
- Total knee replacement (TKR): 10-14 days (approximately 2 weeks) 2
Clinical Trial Evidence for Orthopedic Surgery
The ADVANCE trials (ADVANCE-1, ADVANCE-2, and ADVANCE-3) demonstrated apixaban's efficacy in 11,659 patients undergoing elective hip or knee replacement 1:
- ADVANCE-3 (hip replacement): Apixaban showed superior efficacy compared to enoxaparin, with total VTE/all-cause death of 1.39% vs 3.86% (p<0.0001) 1
- ADVANCE-2 (knee replacement): Apixaban demonstrated superiority with 15.06% vs 24.37% event rate (p<0.0001) 1
- Major bleeding rates were comparable to enoxaparin across all studies (0.60-0.82% for apixaban) 1
Postoperative Resumption After Interruption
When patients are already on apixaban for other indications (atrial fibrillation or VTE treatment) and require surgery, the 2022 ACCP guidelines provide clear resumption protocols 3:
Resumption Timing Based on Bleeding Risk:
- Low bleeding risk procedures: Resume apixaban 24 hours post-procedure
- Moderate bleeding risk procedures: Resume 48-72 hours post-procedure
- High bleeding risk procedures: Resume 48-72 hours post-procedure with adequate hemostasis
No bridging with heparin is recommended when interrupting DOACs perioperatively, except in very high thrombotic risk patients 2.
Emerging Evidence for Non-Orthopedic Surgery
Recent high-quality studies demonstrate apixaban's safety and efficacy beyond orthopedic surgery:
- Gynecologic cancer surgery (2024): Apixaban showed significantly lower 30-day VTE rates (0.6%) compared to enoxaparin (6.2%), with similar bleeding complications 4
- Bariatric surgery (2024): Zero post-discharge VTEs with apixaban versus 0.5% without prophylaxis (p=0.02), with minimal self-resolving bleeding events 5
- Radical cystectomy (2025): No significant difference in VTE rates between apixaban and enoxaparin, with comparable safety profiles 6
- Abdominoplasty (2025): Apixaban demonstrated safety with 1.1% VTE rate and no hematomas in treated patients 7
Important Caveats and Contraindications
When NOT to Use Apixaban Postoperatively:
- Active bleeding or concern for postoperative bleeding (hypotension, unexplained tachycardia with hematocrit drop >6%, or hematocrit drop >9%) 5
- Patients already on therapeutic anticoagulation preoperatively (except aspirin) 5
- Procedures with very high bleeding risk may require delayed initiation beyond 12-24 hours 2
Renal Function Considerations:
For patients with CrCl 30-50 mL/min receiving apixaban for orthopedic prophylaxis, the dose is reduced to 150 mg once daily (for dabigatran comparison; apixaban dosing remains 2.5 mg BID but requires monitoring) 2.
Practical Algorithm for VTE Prophylaxis Decision
For major orthopedic surgery (hip/knee replacement):
- Start apixaban 2.5 mg BID at 12-24 hours post-surgery
- Continue for 5 weeks (hip) or 2 weeks (knee)
For other high-risk surgeries (gynecologic cancer, bariatric, urologic):
- Consider apixaban 2.5 mg BID for 28-30 days post-discharge
- Exclude if active bleeding concerns or on therapeutic anticoagulation
- Monitor for bleeding complications in first week
For patients already on apixaban requiring surgery:
- Stop 1 day before low-moderate bleed risk procedures
- Stop 2 days before high bleed risk procedures 3
- Resume 24-72 hours post-procedure based on bleeding risk and hemostasis
Comparative Safety Note
One concerning study 8 found increased odds of thrombotic events with apixaban versus aspirin after THA/TKA, but this contradicts FDA trial data 1 and likely reflects selection bias (sicker patients receiving apixaban). The FDA approval trials remain the gold standard for orthopedic prophylaxis efficacy.